Table 2.
HFpEF characteristics and medications
| Disease related characteristics | ||
| NYHA class II | 10 (42%) | |
| NYHA class III | 10 (42%) | |
| NYHA class IV | 4 (17%) | |
| Six min walk distance, m | 402 ± 42 | |
| B-Type natriuretic peptide, pg/mL | 150 ± 26 | |
| Diabetes | 10 (42%) | |
| COPD | 2 (8%) | |
| CAD | 6 (25%) | |
| Hypertensive | 20 (83%) | |
| Echocardiography | Value | Reference Range |
| Ejection fraction, % | 62 ± 1 | ≥55 |
| LV IVSD, cm | 1.1 ± 0.1 | 0.6 – 1.1 |
| LV PWD, cm | 1.1 ± 0.1 | 0.6 – 0.9 |
| LV ID diastole, cm | 4.5 ± 0.2 | 3.9 – 5.3 |
| LV ID systole, cm | 3.0 ± 0.1 | 2.0 – 4.0 |
| Peak E wave, cm/s | 84 ± 7 | -- |
| Peak A wave, cm/s | 96 ± 11 | -- |
| E/A ratio | 1.1 ± 0.2 | 0.6 – 1.32 |
| E' lateral wall, cm/s | 7 ± 1 | 13–28 |
| E/E' ratio | 13 ± 2 | ≤ 8 |
| Mitral E-wave deceleration time, ms | 246 ± 14 | 142–258 |
| Medications | ||
| Beta receptor blocker | 11 (46%) | |
| ACEi or ARB | 15 (63%) | |
| Loop diuretics | 22 (92%) | |
| Aldosterone antagonist | 16 (67%) | |
| Statin | 18 (75%) | |
| Nitrates | 5 (21%) | |
| Calcium channel blockers | 3 (13%) |
HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association; LV IVSD, left ventricle interventricular septum diameter; LV PWD, left ventricle posterior wall diameter; LV ID, left ventricle internal diameter; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. Data are mean ± SEM or % of group.